Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$496.01M+175.19%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Blair Jackson
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2,050
- Beta
- 0.26
- Country
- IE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.10
Financials
Revenue
$496.01M+175.2%Net Income
$501.0KEBITDA
$54.32MFree Cash Flow
$137.04M+4149.2%EPS (diluted)
$0.00Shares Outstanding (diluted)
166.61M+9.9%Operating Expenses
$330.52MCash & Debt
$656.58MReturn of Capital
$0.00Revenue by Segment (annual)
$1.18BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.48B | $241.66M | $1.47 |
| 2024 | $1.56B | $367.07M | $2.22 |
| 2023 | $1.66B | $355.76M | $2.14 |
| 2022 | $1.11B | $-158.27M | $-0.97 |
| 2021 | $1.17B | $-48.17M | $-0.30 |
| 2020 | $1.04B | $-110.86M | $-0.70 |
| 2019 | $1.17B | $-196.62M | $-1.25 |
| 2018 | $1.09B | $-139.31M | $-0.90 |
| 2017 | $903.37M | $-157.94M | $-1.03 |
| 2016 | $745.69M | $-208.44M | $-1.38 |
| 2015 | $628.34M | $-227.16M | $-1.52 |
| 2014 | $618.79M | $-30.06M | $-0.21 |
| 2013 | $575.55M | $24.98M | $0.19 |
| 2012 | $575.55M | $24.98M | $0.19 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ALKS's reported EPS growth of 17.0% a year over 13 years.
- EPS in 5 years
- $3.22
- Implied price
- $61.12
- Return from $41.75
- 7.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.39 — -27.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| 7.0% | -8.5% | -4.6% | -1.3% | 1.6% | 4.3% |
| 12.0% | -4.2% | -0.2% | 3.3% | 6.4% | 9.1% |
| 17.0% | 0.0% | 4.3% | 7.9% | 11.1% | 14.0% |
| 22.0% | 4.3% | 8.7% | 12.5% | 15.9% | 18.9% |
| 27.0% | 8.6% | 13.2% | 17.1% | 20.6% | 23.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120-4.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·10d ago·Positive
…LUMRYZ's IH indication could drive incremental revenue, leveraging existing commercial infrastructure and delivering operating leverage with a limited SG&A increase. ALKS faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales post-March 2028, but the opportunity remains financially meaningful.
View source ↗ - Newszacks.com·13d ago·Neutral
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.
View source ↗ - Newsfool.com·37d ago·Negative
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct equity holdings.
View source ↗ - Newsbusinesswire.com·42d ago·Positive
…rology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hyper…
View source ↗ - Newszacks.com·54d ago·Positive
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $-0.08 per share
Typical surprise +28.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.70 vs $-0.03beat
- Tue, May 5$-0.40 vs $-0.57beat
- Wed, Feb 25$0.34 vs $0.43miss
- Tue, Oct 28$0.49 vs $0.37beat
- Tue, Jul 29$0.52 vs $0.41beat
- Thu, May 1$0.13 vs $0.25miss
Estimates and results for ALKS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALKS officers and directors.
- Bought
- —
- Sold
- $7.0m
0 trades
22 trades
- Gaffin David Josephsold
- Gaffin David Josephsold
- Hopkinson Craig C.sold
- Nichols Christian Toddsold
- Nichols Christian Toddsold
- Snyderman Nancy Lynn Mdsold
- Hopkinson Craig C.sold
- Gaffin David Josephsold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 7, 2026 (39d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.